Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-cash Items (2016 - 2025)

Sutro Biopharma's Non-cash Items history spans 10 years, with the latest figure at $5.2 million for Q3 2025.

  • For Q3 2025, Non-cash Items fell 18.83% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $5.2 million, down 18.83%, while the annual FY2024 figure was $6.4 million, 3441.38% up from the prior year.
  • Non-cash Items for Q3 2025 was $5.2 million at Sutro Biopharma, down from $6.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $58.1 million in Q1 2021 and bottomed at $180000.0 in Q4 2023.
  • The 5-year median for Non-cash Items is $5.7 million (2023), against an average of $9.7 million.
  • The largest annual shift saw Non-cash Items crashed 98.11% in 2022 before it soared 3441.38% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $15.0 million in 2021, then plummeted by 85.38% to $2.2 million in 2022, then crashed by 91.77% to $180000.0 in 2023, then skyrocketed by 3441.38% to $6.4 million in 2024, then fell by 19.14% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Non-cash Items are $5.2 million (Q3 2025), $6.6 million (Q2 2025), and $6.6 million (Q1 2025).